Irbesartan Sandoz

Irbesartan, the active ingredient in Irbesartan Sandoz, is a Angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to lower high blood pressure and to protect kidney function in patients with diabetic kidney disease. GNH USA supplies Irbesartan Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the class of Angiotensin II receptor blockers and is used to manage conditions related to the renin‑angiotensin system. Hypertension: reduces elevated blood pressure and lowers cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Renal protection in diabetes: helps preserve kidney function by reducing intraglomerular pressure.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Nasal congestion - Diarrhoea or abdominal discomfort - Elevated serum potassium (mild)

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hyperkalemia - Acute kidney injury or worsening renal function - Symptomatic hypotension - Hepatic enzyme elevation - Myocardial infarction (rare)

Irbesartan should be used with careful clinical monitoring. - Blood pressure monitoring: check regularly to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor for hyperkalaemia, especially with concomitant potassium‑sparing agents. - Pregnancy warning: contraindicated in pregnancy (Category D) due to fetal toxicity. - Elderly patients: start at lower dose and monitor for renal impairment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines that affect potassium balance or renal function. Major Interactions (Avoid): - Aliskiren (in patients with diabetes): combined use can increase risk of renal impairment. - ACE inhibitors: concurrent use raises the chance of severe hyperkalaemia and renal dysfunction. - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: can reduce antihypertensive effect and impair renal function. - Thiazide diuretics: may enhance hypotensive response; monitor blood pressure. - Lithium: increased lithium levels; monitor for signs of toxicity.